Oral antidiabetic drugs
Authors:
Z. Vlasáková; T. Pelikánová
Authors‘ workplace:
Centrum diabetologie
; Přednosta: prof. MUDr. Terezie Pelikánová, DrSc.
; Institut klinické a experimentální medicíny, Praha
Published in:
Prakt. Lék. 2011; 91(1): 28-32
Category:
40th Anniversary IKEM
Overview
Glycaemic control is important therapeutic target for Type 2 diabetic patients. These patients present with
- insulin deficiency,
- insulin resistance and
- alpha cell dysfunction.
To overcome failures of current therapy and to address the different underlying defects of pathology of Type 2 diabetes, a combined therapy of oral antidiabetic agents is used. The development of new agents that affect an insulin secretion, progression of beta cell failure and alpha cell dysfunction could be considered as an additional objective for the management of diabetes. The combination of such agents with other oral antidiabetic drugs could provide a long-term effect on good glycaemic control and reduce diabetic and cardiovascular complication in Type 2 diabetic patients.
Key words:
diabetes mellitus Type 2, insulin secretion, insulin resistance.
Sources
1. Ahrén, B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care, 2007, 30, p.1344-1350.
2. Ahrén, B., Schweizer, A., Dejager, S. et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2009, 94, p. 1236-1243.
3. Ban, K., Hui, S., Drucker, D.J. et al. Cardiovascular consequence of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J. Am. Soc. Hypertens. 2009, 3, p. 245-259.
4. Campbell, R.K., White, J.R. Jr. More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ. 2008, 34, p. 518-534.
5. De Sousa C., Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat. Rev. Drug Discov. 2009, 8, p. 361-367.
6. Drucker, D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol. Metab. 2005, 1, p. 22-31.
7. Gangji, A.S., Cukierman, T., Gerstein, H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30, p. 389-394.
8. Gerich, J., Raskin, P., Jean-Louis, L. et al. PRESERVE-beta: two year efficacy and safety of initial combination therapy with nateglinide or gliburide plus metformin. Diabetes Care 2005, 28, p. 2093-2099.
9. Goldstein, B., Feinglos, M., Lunceford, J. et al. Effect of initial combination therapy with sigagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30, p. 1979-1987.
10. Kahn, S.E., Haffner, S.M., Heise, M.A. et al. Glycemic durability of rosiglitazone, metformin, or gliburide monotherapy. N. Engl. J. Med. 2006, 355, p. 2427-2443.
11. Lincoff, A.M., Wolski, K., Nicholls, S.J. et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomised trials. JAMA 2007, 298, p. 1180-1188.
12. Lovshin, J.A., Drucker, D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5, p. 262-269.
13. Nissen, S.E., Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, p. 2457-2471.
14. Ray, K.K., Seshasai, S.R.K., Wijesuriya, S. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373, p. 1765-1772.
15. Shaw, J.S., Wilmot, R.L., Kilpatrick, E.S. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet. Med. 2007, 24, p. 1160-1163.
16. Singh, S., Loke Y.K., Furberg, C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007, 30, p. 2248-2254.
17. Skyler, J.S., Bergenstal, R., Bonow, R.O. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009, 32, p. 187-192.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352, p. 854-865.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2011 Issue 1
Most read in this issue
- The evaluation of patients for the kidney transplantation waiting list
- Oral antidiabetic drugs
- Diabetes center and diabetology program in IKEM
- The latest news in the prevention and management of diabetic foot disease, the podiatric programme at IKEM